scispace - formally typeset
B

Bernardo Stutz

Researcher at Yale University

Publications -  20
Citations -  901

Bernardo Stutz is an academic researcher from Yale University. The author has contributed to research in topics: Dopamine & Medicine. The author has an hindex of 10, co-authored 16 publications receiving 685 citations. Previous affiliations of Bernardo Stutz include Federal University of Rio de Janeiro & University of Newcastle.

Papers
More filters
Journal ArticleDOI

Vaginal Exposure to Zika Virus during Pregnancy Leads to Fetal Brain Infection.

TL;DR: A mouse model of vaginal ZIKV infection is established and it is demonstrated that, unlike other routes, ZikV replicates within the genital mucosa even in wild-type (WT) mice.
Journal ArticleDOI

Molecular and cellular reorganization of neural circuits in the human lineage

TL;DR: Comparing transcriptome and histology of human and nonhuman primate brains reveals changes that make humans unique, and diverse molecular and cellular features of the phylogenetic reorganization of the human brain across multiple levels, with relevance for brain function and disease.
Journal ArticleDOI

Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson's Disease.

TL;DR: The regulation and functions of AMPK are described, the controversies in the field are evaluated, and the potential of targeting AMPK signaling as a neuroprotective treatment for PD is assessed.
Journal ArticleDOI

Inhibition of Choline Acetyltransferase as a Mechanism for Cholinergic Dysfunction Induced by Amyloid-β Peptide Oligomers

TL;DR: It is found that AβOs selectively bind to ∼50% of cultured cholinergic neurons, suggesting that ChAT is fully inhibited in AβO-targeted neurons, and oxidative damage may be involved in ChAT inhibition.
Journal ArticleDOI

Altered Cortical and Hippocampal Excitability in TgF344-AD Rats Modeling Alzheimer's Disease Pathology

TL;DR: The observed differences in neurophysiological activities in TgF344-AD rats, which mirror several abnormalities described in AD patients, may be used as promising markers to monitor disease-modifying therapies.